Cargando…

Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study

Limited data are available about mitotane-nduced hyperlipidemia. We retrospectively analyzed lipid data in 38 patients with adrenocortical carcinoma (ACC) who received mitotane therapy with emphasis on HDL cholesterol (HDL-c) and clinical predictors of lipid changes. At baseline, the mean levels of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shawa, Hassan, Deniz, Ferhat, Bazerbashi, Hadil, Hernandez, Mike, Vassilopoulou-Sellin, Rena, Jimenez, Camilo, Habra, Mouhammed Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848058/ https://www.ncbi.nlm.nih.gov/pubmed/24348556 http://dx.doi.org/10.1155/2013/624962

Ejemplares similares

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

Durable Effect of Radioactive Iodine in a Patient with Metastatic Follicular Thyroid Carcinoma
por: Carhill, Aubrey A., et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials
por: Kroiss, Matthias, et al.
Publicado: (2019)

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options
por: Al-Ward, Ruaa, et al.
Publicado: (2022)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature
por: Economides, Minas P., et al.
Publicado: (2020)

Adjuvant Therapy in Adrenocortical Carcinoma: Reflections and Future Directions
por: Bedrose, Sara, et al.
Publicado: (2020)

Effect of Mitotane on Male Gonadal Function
por: Innocenti, Federica, et al.
Publicado: (2023)

SAT-175 Trial in Progress Interim Report: A Phase II Clinical Trial Using Single Agent Cabozantinib in Advanced Adrenocortical Carcinoma
por: Bedrose, Sara Shokry Daniel, et al.
Publicado: (2020)

Dyslipidemia causes overestimation of plasma mitotane measurements
por: Paci, Angelo, et al.
Publicado: (2016)

Health profiles of 996 melanoma survivors: the M. D. Anderson experience
por: Stava, Charles, et al.
Publicado: (2006)

High‐Dose Mitotane‐Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma
por: Pape, Elise, et al.
Publicado: (2017)

Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma
por: Warde, Kate M, et al.
Publicado: (2022)

FRI191 Changes In The Incidence And Geographical Distribution Of Adrenocortical Carcinoma: A Retrospective Analysis Of A State Cancer Registry
por: Brondani, Vania B, et al.
Publicado: (2023)

Role of Mitotane in Adrenocortical Carcinoma – Review and State of the art
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures
por: van Koetsveld, Peter M, et al.
Publicado: (2019)

Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma
por: Germano, Antonina, et al.
Publicado: (2020)

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review
por: Bianchini, Marta, et al.
Publicado: (2021)

SAT313 Therapeutic Dosing Of Steroids In Patients On Mitotane
por: Pham, Christopher, et al.
Publicado: (2023)

Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane
por: Cantini, Giulia, et al.
Publicado: (2023)

Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells
por: Bikas, Athanasios, et al.
Publicado: (2019)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study
por: Kimpel, Otilia, et al.
Publicado: (2021)

Response to Immunotherapy in Combination With Mitotane in Patients With Metastatic Adrenocortical Cancer
por: Head, Lia, et al.
Publicado: (2019)

Generation and characterization of a mitotane-resistant adrenocortical cell line
por: Seidel, Eric, et al.
Publicado: (2020)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma
por: Puglisi, Soraya, et al.
Publicado: (2020)

The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging
por: Haider, Malik Salman, et al.
Publicado: (2021)

Biological response of adrenal carcinoma and melanoma cells to mitotane treatment
por: Stelcer, Ewelina, et al.
Publicado: (2022)

Successful treatment of occult hyperadrenocorticism with mitotane but not trilostane in a dog
por: Park, Su‐Min, et al.
Publicado: (2021)

Risk of Hyperlipidemia in Women with Hysterectomy-A Retrospective Cohort Study in Taiwan
por: Li, Pei-Chen, et al.
Publicado: (2018)

Response to Letter to the Editor From Berruti et al: “Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival”
por: Srougi, Victor, et al.
Publicado: (2022)

Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches
por: Hescot, Ségolène, et al.
Publicado: (2017)

Effects of mitotane treatment on human steroid metabolism: implications for patient management
por: Ghataore, L, et al.
Publicado: (2012)

Mitotane in the treatment of childhood adrenocortical carcinoma: a potent endocrine disruptor
por: Oddie, Philip D, et al.
Publicado: (2018)

Complete Radiological Response of Recurrent Metastatic Adrenocortical Carcinoma to Pembrolizumab and Mitotane
por: Alam, Walid, et al.
Publicado: (2021)

Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma
por: Allegra, Sarah, et al.
Publicado: (2021)

Molecular Mechanisms of Mitotane Action in Adrenocortical Cancer Based on In Vitro Studies
por: Lo Iacono, Marco, et al.
Publicado: (2021)

EDP-mitotane in children: reassuring evidence of reversible side-effects and neurotoxicity
por: Steenaard, Rebecca V., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q57adc2hlrc0b1da0c0t61mjnf